Skip to Content

Afinitor Approval History

Afinitor (everolimus) is an oral once-daily inhibitor of mTOR indicated for the treatment of patients with advanced HR+, HER2- breast cancer; progressive neuroendocrine tumors of pancreatic origin (PNET); progressive neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin; advanced renal cell carcinoma; and subependymal giant cell astrocytoma (SEGA) and renal angiomyolipomas associated with tuberous sclerosis.

Development History and FDA Approval Process for Afinitor

Feb 26, 2016Approval FDA Approves Afinitor (everolimus) for Progressive, Nonfunctional Gastrointestinal and Lung Neuroendocrine Tumors (NET)
Aug 29, 2012Approval FDA Approves Afinitor Disperz - First Drug Formulated for Children with Rare Brain Tumor
Jul 20, 2012Approval FDA Approves Afinitor for Advanced Breast Cancer
Apr 26, 2012Approval Novartis drug Afinitor approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
May  6, 2011Approval Novartis Gains FDA Approval for Afinitor As First New Treatment in Nearly Three Decades for Patients With Advanced Pancreatic NET
Nov  1, 2010Approval FDA Approves New Indication for Afinitor
Mar 30, 2009Approval Afinitor approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.